ClinicalTrials.gg
RecruitingNCT06327672ESP-INOCAUpdated Mar 28, 2024

INOCA Spanish National Registry

An observational study in Non-Obstructive Coronary Atherosclerosis, Ischemia and Coronary Disease, sponsored by Eva Rumiz González. Recruiting at 3 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-28.

Sponsored by Eva Rumiz González · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Ischemia with a site in Spain — 5 open to participants now, 8 under way, 1 of them phase 3. Ischemia · Spain.

Planned enrollment
3rd of 11
1,000 · median 200
Started
2024
with 1 other
Observational
11 of 27
2 open now
Registered
23rd of 27
by date

Among the 27 studies in Ischemia with a site in Spain, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2024, is one of 11 observational ones, and was the 23rd registered.

Ischemia

545 studies on the registry are indexed under Ischemia; 71 are open to participants now.

Browse Ischemia studies →

Open to participants now

5 of the 27 studies in Ischemia with a site in Spain are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 44 Ischemia studies recruiting now, 34 (77%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Ischemia with a site in Spain, or all of them as a file.
02

Study summary

Coronary atherosclerosis is the most common cause of ischaemic heart disease. About 40-50% of patients with symptoms and documented ischaemia on non-invasive tests do not show obstructive coronary artery disease on coronary angiography. This cause of ischaemic heart disease called INOCA (Ischemic Non-Obstructive Coronary Artery), far from having a benign prognosis, is associated with an increase in major adverse cardiac events (MACE) as well as increased functional limitation. The current European Society of Cardiology clinical practice guidelines for the management of chronic coronary syndrome establish for the first time a IIa recommendation for the invasive analysis of coronary flow reserve (CFR) and microvascular resistance index (MRI) in symptomatic patients with INOCA. The acetylcholine (Ach) test, based on intracoronary (ic) administration, is established as indication IIb for the assessment of micro or macrovascular vasospasm in patients with suspected vasospastic angina (VSA) (4). A national multicentre registry would allow us to determine the prevalence of INOCA and its different endotypes in our setting.

Read the detailed description

Multicentre, observational, longitudinal, prospective study on INOCA patients undergoing invasive coronary function testing.

Microvascular angina (MVA) is defined according to the standardized diagnostic criteria of COVADIS (Coronary Vasomotion Disorders International Study Group): symptoms of myocardial ischaemia, unobstructed coronary arteries and demonstrated coronary microvascular dysfunction (CFR \< 2 and/or IMR >25), or microvascular spasm on Ach test. Diagnosis of coronary microvascular spasm requires provocation and reproduction of symptoms, ischaemic EKG changes, in the absence of epicardial spasm during ACh testing. The diagnosis of VSA requires that 3 conditions are met during ACh testing: 1) clinically significant epicardial vasoconstriction (≥90%); 2) reproduction of chest pain; and 3) ischaemic EKG changes.

Definition of adverse events: Myocardial infarction (MI) will be defined according to the fourth universal definition and subclassified according to type. Ischaemia revascularization will be defined as all percutaneous coronary intervention (PCI) or Coronary Artery Bypass Grafting (CABG) occurring after the baseline procedure and justified by recurrent symptoms or objective evidence of significant ischaemia on non-invasive stress tests. Heart failure will be defined as a hospital admission > 24 hours with any of the following symptoms and signs: worsening dyspnea, fatigue, fluid overload, pulmonary oedema, elevated venous pressure and need for intravenous diuretics or inotropics. Visits to the emergency department for chest pain will be considered to be those in which there is suspicion of a coronary cause.

All events will be identified and quantified from patient records, including inpatient ward admissions and emergency department visits.

03

Conditions studied

  • Non-Obstructive Coronary Atherosclerosis
  • Ischemia
  • Coronary Disease

Keywords

  • Microvascular dysfunction
  • Endothelial dysfunction
  • Myocardial ischemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with angina and no obstructive coronary artery disease on coronary angiography, as well as those with angina equivalent symptoms and ischaemia on non-invasive tests (exercise stress test, cardiac magnetic resonance imaging, stress echocardiography, SPECT) in the absence of obstructive coronary artery disease, will be prospectively included. They must have undergone an invasive coronary function test. The absence of obstructive coronary artery disease will be defined as the presence of stenosis with a diameter \<50% or >/= 50% and a negative functional test.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients > 18 years.
  • Anginal symptoms.
  • Anginal equivalent with positive myocardial ischaemia test.
  • Absence of obstructive coronary artery disease (diameter stenosis \<50% or >50% with a FFR>0.80).
  • Patients undergoing invasive coronary function test.
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Failure to meet inclusion criteria.
  • Patients with moderate-severe valvular heart disease.
  • Patients with structural heart disease.
  • Elevation of markers of myocardial necrosis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Prevalence of INOCA endotypes.

    To determine the prevalence of the different INOCA endotypes in our setting through a nationwide registry.

    Time frame: 12 months

Secondary outcomes

  1. Incidence of combined event: death from all causes, acute myocardial infarction, readmission for heart failure and consultation for chest pain in the emergency department.

    To determine the long-term prognosis of the different INOCA subtypes, through analysis of the combined event: death from all causes, acute myocardial infarction, readmission for heart failure and consultation for chest pain in the emergency department.

    Time frame: 24 months

  2. Targeted pharmacological treatment

    To determine the impact of targeted pharmacological treatment in INOCA patients.

    Time frame: 24 months

  3. Prognostic markers.

    To identify prognostic markers.

    Time frame: 24

  4. INOCA and risk of heart failure with preserved ejection fraction.

    To evaluate the association between INOCA patients and the development of heart failure with preserved ejection fraction.

    Time frame: 24 months

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2024; primary completion for Mar 2025, 12 months later.

Of 48 non-industry observational studies under Ischemia, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 24. This study's planned 12 months is below that.

Counting every sponsor, half of 70 studies reached it within 35 months; a quarter within 22 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2024
First posted
Mar 25, 2024
StartEst.
Mar 24, 2024
Primary completionEst.
Mar 2025
CompletionEst.
Mar 2026
Last update
Mar 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06327672
Lead sponsor
Eva Rumiz González
Collaborators
Hospital San Carlos, Madrid, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa, Hospital Universitario Virgen de la Arrixaca, University Hospital Gregorio Marañón, Hospital Clínico Universitario de Valladolid, Hospital Universitario Puerta del Mar, Hospital Universitari de Bellvitge, Hospital Universitario La Fe, Hospital Clínico Universitario de Valencia, Hospital Universitario La Paz, Hospital General Universitario de Alicante, Complejo Hospitalario Universitario de Huelva, Hospital General Universitario de Castellón, Hospital de Manises, Hospital Clinic of Barcelona, Hospital Miguel Servet, Hospital Clínico Universitario Lozano Blesa, Hospital Donostia, Hospital General Universitario Elche, Hospital Universitario Virgen del Rocio, Hospital de la Ribera, Hospital de la Santa creu i Sant Pau - Barcelona, Hospital Virgen de la Salud, Hospital Universitario San Juan de Alicante, Hospital Universitario de Torrevieja, University Hospital of the Nuestra Señora de Candelaria, Hospital de Basurto, Hospital Universitario Ramon y Cajal, Hospital Universitario Fundación Jiménez Díaz, Puerta de Hierro University Hospital, Hospital Universitario 12 de Octubre, University of Salamanca, Hospital Universitario Marqués de Valdecilla, Hospital Clinico Universitario de Santiago, Complexo Hospitalario Universitario de A Coruña
Responsible party
Eva Rumiz González (Principal Investigator, Hospital General Universitario de Valencia) — Sponsor-investigator
First posted
Mar 25, 2024
Start date
Mar 24, 2024 (estimated)
Primary completion
Mar 2025 (estimated)
Completion
Mar 2026 (estimated)
Last update
Mar 28, 2024

Study contacts

Eva Rumiz, MD, PhD
Contact
evarumizgonzalez@gmail.com
+34 963131800 ext. 446812

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion